WALTHAM, Mass., May 13, 2021 (GLOBE NEWSWIRE) – Eloxx Pharmaceuticals, Inc. (the “Company”) (Nasdaq: ELOX), a leader in targeted ribosomal RNA gene therapies for rare diseases, today announced have launched a public offering subscribed for shares of its ordinary shares. In addition, the Company expects to grant the Underwriters a 30-day option to purchase up to an additional 15% of the Common Shares at the public offering price, less any sales discounts and commissions.
B. Riley Securities, Inc. is acting as sole account manager for the offering. The offer is subject to market and other conditions, and there can be no guarantee as to whether or when the offer can be made, nor as to the actual size or conditions of the offer. .
The common share is being offered in accordance with a pre-registration statement on Form S-3 which was previously declared effective by the Securities and Exchange Commission (SEC) on November 26, 2018. This offering is being made only by way of a prospectus. writing and prospectus supplement forming part of the registration statement. A preliminary prospectus supplement relating to and describing the terms of the Offer has been filed with the SEC and is available on the SEC’s website at www.sec.gov. The final terms of the offer will be disclosed in a final prospectus supplement which will be filed with the SEC. Where available, copies of the preliminary prospectus supplement and accompanying prospectus relating to the offering may also be obtained by contacting: B. Riley Securities, Inc., Attn .: Prospectus Department, 1300 North 17th Street, Suite 1300, Arlington, Virginia 22209, or by phone at 703-312-9580 or by email at [email protected]
This press release does not constitute an offer to sell or the solicitation of an offer to buy the securities, nor will there be any sale of the securities in any jurisdiction in which such an offer, solicitation or sale would be. illegal before registration or qualification. under the securities laws of that jurisdiction.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of present and historical fact contained in this press release, including, without limitation, statements regarding the expected price and the closing of the proposed offering, are forward-looking statements. Forward-looking statements may be identified by the words “aim”, “may”, “will”, “would”, “should”, “expect”, “explore”, “plan”, “anticipate”, “could” , “Intent”, “target”, “project”, “contemplate”, “believe”, “estimate”, “predict”, “potential”, “seek” or “continue” or the negative of these terms similar expressions, well that not all forward-looking statements contain these words.
Forward-looking statements are based on management’s current plans, estimates, assumptions and projections based on information currently available to us. Forward-looking statements are subject to known and unknown risks, uncertainties and assumptions, and actual results or results may differ materially from those expressed or implied in the forward-looking statements due to various important factors, including, but not limited to : our ability to advance any product candidate in preclinical or clinical trials; the uncertainty of clinical trial results and the fact that positive results from preclinical studies are not always indicative of positive clinical results; the scope, pace and progress of our preclinical studies and clinical trials and other research and development activities; the competition for the registration of patients among the drug candidates in development; the impact of the global COVID-19 pandemic on our clinical trials, operations, suppliers, suppliers and employees; our ability to raise the capital necessary to finance our operations; the cost of filing, prosecuting, defending and enforcing claims of patents and other intellectual property rights; our ability to obtain financing in the future through product licensing, public or private private equity, debt financing or otherwise; general business conditions, regulatory environment, competition and market for our products; and the business ability and judgment of personnel, as well as the availability of qualified personnel and other significant risk factors discussed in our other documents filed with the SEC, including, but not limited to, our annual report on Form 10-K for the year ended December 31, 2020 and our quarterly report on Form 10-Q for the quarter ended March 31, 2021. All forward-looking statements speak only as of the date of this press release and, Except as required by applicable law, we have no obligation to update or revise any forward-looking statements contained herein, whether as a result of new information, future events, changes in circumstances or otherwise.
SOURCE: Eloxx Pharmaceuticals, Inc.